Advanced Filters
noise
Found 1,281 clinical trials

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

18 - 74 years of age All Phase 3
J Julianna Lizzul

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, …

18 - 65 years of age All Phase 4
F Felix Mueller, PD Dr. med.

Antidepressant Response of DMT Masked With Propofol

The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.

21 years of age All Phase N/A
K Kyoung-Sae Na, MD, PhD

Application of the Web-based Acceptance and Commitment Therapy for Depression

PROSPECTIVE INTERVENTION STUDY; EFFICACY OF WEB-BASED ACCEPTANCE AND COMMITMENT THERAPY

19 - 65 years of age All Phase N/A
S Sigal Zilcha-Mano, PhD

An Individual-specific Synchrony Signature

This study aims to establish synchrony as an individual-specific mechanism of therapeutic change and offers novel insights into the mechanisms of curative interpersonal processes. The study identifies individual-specific trait-like synchrony signature and investigates the associations between synchrony signature, the individual's trait-like characteristics, and mental health, among participants diagnosed with Major …

18 - 65 years of age All Phase N/A

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike …

18 - 64 years of age All Phase 2

Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation

This study aims to better understand the mechanisms of action of antidepressants, but also the neural correlates of motivation deficits. One hundred patients with a moderate to severe major depressive episode will be enrolled in this prospective multicenter study. The objective will be to predict the therapeutic response to two …

18 years of age All Phase N/A

Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients with Major Depressive Disorder

This study aimed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in patients with major depressive disorder (MDD) who exhibit suboptimal early response to antidepressant treatment. Additionally, it sought to investigate the impact of FMT on biological indicators, including intestinal microbiota and metabolites, in individuals with MDD

18 - 65 years of age All Phase N/A

Effect of Aerobic Exercise on Biomarkers in Depression

This study aims to investigate changes in the levels of biomarkers (IGF-1, FGF2, and EGF) involved in neuron development in patients diagnosed with major depression through the effects of breathing exercises and aerobic exercise, as well as to examine the levels of biomarkers (TNF-α, IL-6, and IL-1) and oxidative stress …

18 - 40 years of age All Phase N/A

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

18 years of age All Phase 3

Simplify language using AI